Silo Pharma Inc. (SILO)
Silo Pharma Statistics
Share Statistics
Silo Pharma has 4.48M shares outstanding. The number of shares has increased by 57.7% in one year.
| Shares Outstanding | 4.48M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 4.29M |
| Failed to Deliver (FTD) Shares | 23 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 101.86K, so 2.27% of the outstanding shares have been sold short.
| Short Interest | 101.86K |
| Short % of Shares Out | 2.27% |
| Short % of Float | 2.37% |
| Short Ratio (days to cover) | 0.98 |
Valuation Ratios
The PE ratio is -1.2 and the forward PE ratio is -1.74.
| PE Ratio | -1.2 |
| Forward PE | -1.74 |
| PS Ratio | 61.51 |
| Forward PS | null |
| PB Ratio | 0.72 |
| P/FCF Ratio | -1.38 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Silo Pharma Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.9, with a Debt / Equity ratio of 0.
| Current Ratio | 9.9 |
| Quick Ratio | 9.9 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -791.87 |
Financial Efficiency
Return on equity (ROE) is -0.6% and return on capital (ROIC) is -62.42%.
| Return on Equity (ROE) | -0.6% |
| Return on Assets (ROA) | -0.48% |
| Return on Capital (ROIC) | -62.42% |
| Revenue Per Employee | 24.03K |
| Profits Per Employee | -1.23M |
| Employee Count | 3 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 25.17% in the last 52 weeks. The beta is 1.36, so Silo Pharma 's price volatility has been higher than the market average.
| Beta | 1.36 |
| 52-Week Price Change | 25.17% |
| 50-Day Moving Average | 1.17 |
| 200-Day Moving Average | 1.38 |
| Relative Strength Index (RSI) | 70.71 |
| Average Volume (20 Days) | 3.30M |
Income Statement
In the last 12 months, Silo Pharma had revenue of 72.10K and earned -3.70M in profits. Earnings per share was -1.2.
| Revenue | 72.10K |
| Gross Profit | 66.26K |
| Operating Income | -3.86M |
| Net Income | -3.70M |
| EBITDA | -3.63M |
| EBIT | -3.86M |
| Earnings Per Share (EPS) | -1.2 |
Balance Sheet
The company has 3.52M in cash and 0 in debt, giving a net cash position of 3.52M.
| Cash & Cash Equivalents | 3.52M |
| Total Debt | 0 |
| Net Cash | 3.52M |
| Retained Earnings | -10.87M |
| Total Assets | 8.57M |
| Working Capital | 7.22M |
Cash Flow
In the last 12 months, operating cash flow was -3.22M and capital expenditures -2, giving a free cash flow of -3.22M.
| Operating Cash Flow | -3.22M |
| Capital Expenditures | -2 |
| Free Cash Flow | -3.22M |
| FCF Per Share | -1.05 |
Margins
Gross margin is 91.9%, with operating and profit margins of -5.35K% and -5.13K%.
| Gross Margin | 91.9% |
| Operating Margin | -5.35K% |
| Pretax Margin | -5.04K% |
| Profit Margin | -5.13K% |
| EBITDA Margin | -5.03K% |
| EBIT Margin | -5.35K% |
| FCF Margin | -4.47K% |
Dividends & Yields
SILO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -63.49% |
| FCF Yield | -37.98% |
Analyst Forecast
Currently there are no analyst rating for SILO.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Sep 15, 2022. It was a backward split with a ratio of 1:50.
| Last Split Date | Sep 15, 2022 |
| Split Type | backward |
| Split Ratio | 1:50 |
Scores
| Altman Z-Score | 0.28 |
| Piotroski F-Score | 1 |